-
Innovation Ranking
NewInnovation Ranking – PI Industries Ltd
PI Industries Ltd (PI Industries) is an agrochemical company. It is a producer and supplier of agrochemicals products in granular formulations. It offers a wide range of products including insecticides, fungicides, herbicides, specialty products, plant nutrients, and other plant fertilizers. PI Industries’ major services include R&D services, custom synthesis and manufacturing services, distribution services, regulatory services, manufacturing services, application development, and marketing solutions. The company sells its products through retail points and channel partners. It has operational presence across Japan,...
-
Product Insights
Pied de Borne
Pied de Borne is a Hydro project located in Occitanie, France. The project is owned by Electricite de France SA. The project came online in 1965. Empower your strategies with our Pied de Borne report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AP-301 in Hyperphosphatemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AP-301 in Hyperphosphatemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AP-301 in Hyperphosphatemia Drug Details: VS-505 is under development for the treatment of...
-
Company Insights
Innovation and Patenting activity of PI Industries Ltd Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of PI Industries Ltd Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Daratumumab in Refractory Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Daratumumab in Refractory Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Daratumumab in Refractory Chronic Lymphocytic Leukemia (CLL) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Daratumumab in Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Daratumumab in Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Daratumumab in Chronic Lymphocytic Leukemia (CLL) Drug Details: Daratumumab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Daratumumab in Lymphoblastic Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Daratumumab in Lymphoblastic Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Daratumumab in Lymphoblastic Lymphoma Drug Details: Daratumumab ((HuMax-CD38, JNJ-54767414, Darzalex, Dalinvi, Darzalex...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Daratumumab in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Daratumumab in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Daratumumab in Acute Lymphocytic Leukemia (ALL,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Daratumumab in Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Daratumumab in Precursor B-Cell Lymphoblastic Leukemia-Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Daratumumab in Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Drug Details: Daratumumab...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Daratumumab in Plasma Cell Neoplasm
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Daratumumab in Plasma Cell Neoplasm report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Daratumumab in Plasma Cell Neoplasm Drug Details: Daratumumab ((HuMax-CD38, JNJ-54767414, Darzalex,...